Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.

Zhao, Xiao-Yan; Subramanyam, Babu; Sarapa, Nenad; Golfier, Sven; Dinter, Harald

Zhao, Xiao-Yan; Subramanyam, Babu; Sarapa, Nenad; Golfier, Sven; Dinter, Harald.

Afiliação

Zhao XY; Bayer Pharmaceuticals, Biologics Research, San Francisco, CA,USA.
Subramanyam B; Bayer Pharmaceuticals, Biologics Research, San Francisco, CA,USA.
Sarapa N; Clinical Sciences, Whippany, NJ,USA.
Golfier S; Therapeutic Research Oncology, Berlin,Germany.
Dinter H; Bayer Pharmaceuticals, Biologics Research, San Francisco, CA,USA.

Clin Cancer Drugs ; 3(2): 76-86, 2016 Oct.

Article em En | MEDLINE | ID: mdl-27853672

Palavras-chave

7D9-MMAE; Amatuximab; Anetumab ravtansine; Antibody (Ab); BMS-986148; DM1 or DM4: maytansinoid tubulin inhibitors; DMOT4039A; MDX-1204; Monomethyl auristatin E (MMAE); RG7787; SS1P; antibody-drug conjugate (ADC); antigen; cancer; chimeric monoclonal antibody; mesothelin; recombinant immunotoxin (RIT); unconjugated antibody

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Cancer Drugs Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Cancer Drugs Ano de publicação: 2016 Tipo de documento: Article